Trial Profile

A Phase 2, Randomized, Open-Label Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Burixafor (Primary) ; Propranolol (Primary) ; Granulocyte colony-stimulating factor receptor agonists
Indications Multiple myeloma
Focus Pharmacokinetics
Sponsors GPCR Therapeutics

05 May 2025 According to an Exicure Inc media release, Topline results from the study are expected in Fall 2025.
05 May 2025 According to an Exicure Inc media release, company announced that it has completed patient enrollment in this ongoing Phase 2 clinical trial.
05 May 2025 Status changed from recruiting to active, no longer recruiting, according to an Exicure Inc media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com